Jci_page_head_homepage_01 Jci_page_head_homepage_02
Hélène Bour-Jordan, Benoît L. Salomon, Heather L. Thompson, Gregory L. Szot, Matthew R. Bernhard, Jeffrey A. Bluestone
Published in Volume 114, Issue 7
J Clin Invest. 2004; 114(7):979–987 doi:10.1172/JCI20483
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 3

Blocking B7-1 but not CTLA-4 restores diabetes in NOD_B7-2_/_ mice. (A) We treated NOD_B7-2_/_ mice with control Ig (triangles; n = 5), anti_B7-1 mAb’s (circles; n = 11), or anti_CTLA-4 mAb’s (squares; n = 8). We followed blood glucose levels weekly after mice reached 8 weeks of age to assess the development of diabetes. Similar results were observed in males and females and were pooled. The incidence of diabetes was 0% in both control Ig and anti_CTLA-4 mAb_treated groups. (B) NOD_B7-2_/_ mice were treated with anti_B7-1 mAb’s between 2 and 4 weeks of age. Percentage of Treg’s was analyzed 2_4 days after the end of the treatment. (C) BDC2.5 cells labeled with CFSE were transferred into adult (8- to 10-week-old) NOD mice or NOD_B7-2_/_ mice treated with control Ig or anti_B7-1 mAb’s. NOD_B7-2_/_ mice were treated with 7 injections of 50 μg anti_B7-1 mAb’s every other day using two different regimens (see Methods for details). The 2 groups gave similar results and were pooled. The results are expressed as the percentage of cycled BDC2.5 cells in the pancreatic LNs (see Figure 1 legend). Histograms represent the mean and standard deviation for each group.